Cancer outcomes and cardiopulmonary toxicities for Black patients with breast cancer treated with proton therapy
JNCI Cancer Spectrum · 2025
DOI: 10.1093/jncics/pkae129 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Cancer Spectrum, 2025. Verfasst von Gurbani Singh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, United States. Hauptthemen laut MEDLINE: Black or African American, Breast Neoplasms, Cardiovascular Diseases, Proton Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Black women have a 40% higher breast cancer mortality rate than White women and are at a higher risk of acquiring cardiovascular disease. Proton therapy can be used to mitigate cardiac radiation exposure; however, proton therapy remains a scarce resource in the United States. We report on the cardiovascular profiles of patients undergoing proton therapy to determine the potential benefit of the therapy for Black women compared with patients of other races.
Methods
We retrospectively analyzed 599 patients with breast cancer who received proton therapy from June 2016 to December 2021 at the Maryland Proton Treatment Center. A variety of sociodemographic, disease, and treatment variables were analyzed using descriptive statistics.
Results
With a median follow-up of 26 months (range = 0.47-90 months), Black patients made up 31.6% of the population and presented with higher rates of hypertension (P < .001), cardiopulmonary conditions (P < .001), and a higher median body mass index (P = .015) compared with the other cohort, a trend that persisted at the time of post–proton therapy follow-up. Black women had higher rates of triple-negative disease (P < .001), with subsequent greater receipt of neoadjuvant chemotherapy (P = .039). Pulmonary events were 2.6 times more likely to occur in Black patients than in the non-Black cohort after proton therapy (odds ratio = 2.60, 95% CI = 1.39 to 4.88; P = .003).
Conclusions
Black women presenting for proton therapy had higher baseline risks of cardiovascular co-morbidities combined with more aggressive breast cancer biology and a subsequent 2.6-fold increased risk of pulmonary events after proton therapy. Our findings support the use of advanced radiation techniques as a means of sparing important organs at risk, especially in historically marginalized populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, United States.
- Department of Radiation Oncology, NYU Langone Health, New York, NY 10016, United States.
- Department of Radiation Oncology, Chesapeake Oncology-Hematology Associates, Glen Burnie, MD 21061, United States.
- Department of Epidemiology and Public Health, Biostatistics and Bioinformatics Division, University of Maryland School of Medicine, Baltimore, MD 21201, United States.
ORCID-Profile: Gurbani Singh, Sravya Koduri, Manaahil Rao, Sarah Ruff, Søren M Bentzen, Elizabeth Nichols, Sarah McAvoy, Melissa A L Vyfhuis
Zitieren
APA
Singh, G., Koduri, S., Rao, M., Kidorf, M., Ruff, S., Patel, A., Bentzen, S. M., Nichols, E., McAvoy, S., & Vyfhuis, M. A. L. (2025). Cancer outcomes and cardiopulmonary toxicities for Black patients with breast cancer treated with proton therapy. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkae129
Vancouver
Singh G, Koduri S, Rao M, Kidorf M, Ruff S, Patel A, et al. Cancer outcomes and cardiopulmonary toxicities for Black patients with breast cancer treated with proton therapy. JNCI Cancer Spectrum. 2025. doi:10.1093/jncics/pkae129
BibTeX
@article{Singh2025,
author = {Singh, Gurbani and Koduri, Sravya and Rao, Manaahil and Kidorf, Meira and Ruff, Sarah and Patel, Akshar and Bentzen, Søren M and Nichols, Elizabeth and McAvoy, Sarah and Vyfhuis, Melissa A L},
title = {Cancer outcomes and cardiopulmonary toxicities for Black patients with breast cancer treated with proton therapy},
journal = {JNCI Cancer Spectrum},
year = {2025},
doi = {10.1093/jncics/pkae129}
}
EUVIMED